Guard Therapeutics International AB (GUARD) - Net Assets
Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has net assets worth Skr55.63 Million SEK (≈ $5.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr70.88 Million ≈ $7.63 Million USD) and total liabilities (Skr15.24 Million ≈ $1.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guard Therapeutics International AB (GUARD) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr55.63 Million |
| % of Total Assets | 78.5% |
| Annual Growth Rate | 19.03% |
| 5-Year Change | -52.36% |
| 10-Year Change | -11.06% |
| Growth Volatility | 350.8 |
Guard Therapeutics International AB - Net Assets Trend (2008–2024)
This chart illustrates how Guard Therapeutics International AB's net assets have evolved over time, based on quarterly financial data. Also explore Guard Therapeutics International AB balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Guard Therapeutics International AB (2008–2024)
The table below shows the annual net assets of Guard Therapeutics International AB from 2008 to 2024. For live valuation and market cap data, see how much is Guard Therapeutics International AB worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr37.97 Million ≈ $4.09 Million |
-43.11% |
| 2023-12-31 | Skr66.73 Million ≈ $7.18 Million |
-62.37% |
| 2022-12-31 | Skr177.36 Million ≈ $19.09 Million |
+0.90% |
| 2021-12-31 | Skr175.78 Million ≈ $18.92 Million |
+120.59% |
| 2020-12-31 | Skr79.69 Million ≈ $8.58 Million |
+51.43% |
| 2019-12-31 | Skr52.62 Million ≈ $5.66 Million |
+1890.54% |
| 2018-12-31 | Skr-2.94 Million ≈ $-316.28K |
-109.19% |
| 2017-12-31 | Skr31.96 Million ≈ $3.44 Million |
+5.37% |
| 2016-12-31 | Skr30.34 Million ≈ $3.26 Million |
-28.93% |
| 2015-12-31 | Skr42.69 Million ≈ $4.59 Million |
-18.31% |
| 2014-12-31 | Skr52.25 Million ≈ $5.62 Million |
+105.59% |
| 2013-12-31 | Skr25.42 Million ≈ $2.74 Million |
-16.88% |
| 2012-12-31 | Skr30.58 Million ≈ $3.29 Million |
+1342.85% |
| 2011-12-31 | Skr2.12 Million ≈ $228.07K |
-31.29% |
| 2010-12-31 | Skr3.08 Million ≈ $331.92K |
+31.87% |
| 2008-12-31 | Skr2.34 Million ≈ $251.71K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guard Therapeutics International AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77210600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr12.29 Million | 32.38% |
| Other Components | Skr797.78 Million | 2101.29% |
| Total Equity | Skr37.97 Million | 100.00% |
Guard Therapeutics International AB Competitors by Market Cap
The table below lists competitors of Guard Therapeutics International AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Site Group International Ltd
AU:SIT
|
$2.30 Million |
|
Oriental Rise Holdings Limited Ordinary Shares
NASDAQ:ORIS
|
$2.31 Million |
|
Sure-Tech Investments LP
TA:STEC
|
$2.31 Million |
|
Limas Indonesia Makmur Tbk
JK:LMAS
|
$2.31 Million |
|
TOMCO ENERGY POST CON.
F:NI41
|
$2.30 Million |
|
Club De Futbol Intercity Sad
MC:CITY
|
$2.29 Million |
|
Falcon Oil & Gas Ltd.
LSE:FOG
|
$2.29 Million |
|
PSYCHED WELLNESS LTD
F:5U9
|
$2.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guard Therapeutics International AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 66,733,000 to 37,966,000, a change of -28,767,000 (-43.1%).
- Net loss of 96,066,000 reduced equity.
- Share repurchases of 64,500,000 reduced equity.
- New share issuances of 64,500,000 increased equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 67,298,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-96.07 Million | -253.03% |
| Share Repurchases | Skr64.50 Million | -169.89% |
| Share Issuances | Skr64.50 Million | +169.89% |
| Other Comprehensive Income | Skr1.00K | +0.0% |
| Other Changes | Skr67.30 Million | +177.26% |
| Total Change | Skr- | -43.11% |
Book Value vs Market Value Analysis
This analysis compares Guard Therapeutics International AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.04x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | Skr1.02 | Skr1.06 | x |
| 2012-12-31 | Skr14.73 | Skr1.06 | x |
| 2013-12-31 | Skr12.24 | Skr1.06 | x |
| 2014-12-31 | Skr15.91 | Skr1.06 | x |
| 2015-12-31 | Skr10.61 | Skr1.06 | x |
| 2016-12-31 | Skr6.21 | Skr1.06 | x |
| 2017-12-31 | Skr2.40 | Skr1.06 | x |
| 2018-12-31 | Skr-0.09 | Skr1.06 | x |
| 2019-12-31 | Skr0.40 | Skr1.06 | x |
| 2020-12-31 | Skr0.51 | Skr1.06 | x |
| 2021-12-31 | Skr1.59 | Skr1.06 | x |
| 2022-12-31 | Skr25.17 | Skr1.06 | x |
| 2023-12-31 | Skr6.63 | Skr1.06 | x |
| 2024-12-31 | Skr3.40 | Skr1.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guard Therapeutics International AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -253.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-253.03%) is below the historical average (-86.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -45.53% | -3358.59% | 0.00x | 3.67x | Skr-1.18 Million |
| 2012 | -6.85% | -167.60% | 0.03x | 1.56x | Skr-5.15 Million |
| 2013 | -20.32% | -722.24% | 0.02x | 1.86x | Skr-7.71 Million |
| 2014 | -11.80% | -18678.79% | 0.00x | 1.11x | Skr-11.39 Million |
| 2015 | -75.94% | 0.00% | 0.00x | 1.21x | Skr-36.68 Million |
| 2016 | -171.67% | 0.00% | 0.00x | 1.40x | Skr-55.11 Million |
| 2017 | -211.62% | 0.00% | 0.00x | 1.37x | Skr-70.84 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-86.41 Million |
| 2019 | -87.47% | 0.00% | 0.00x | 1.21x | Skr-51.29 Million |
| 2020 | -50.56% | 0.00% | 0.00x | 1.14x | Skr-48.26 Million |
| 2021 | -46.74% | 0.00% | 0.00x | 1.08x | Skr-99.74 Million |
| 2022 | -62.45% | 0.00% | 0.00x | 1.14x | Skr-128.49 Million |
| 2023 | -169.82% | 0.00% | 0.00x | 1.28x | Skr-120.00 Million |
| 2024 | -253.03% | 0.00% | 0.00x | 1.47x | Skr-99.86 Million |
Industry Comparison
This section compares Guard Therapeutics International AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,054,194
- Average return on equity (ROE) among peers: -81.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guard Therapeutics International AB (GUARD) | Skr55.63 Million | -45.53% | 0.27x | $2.30 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $40.96 Million |
| AcouSort AB (ACOU) | $15.58 Million | -57.51% | 0.12x | $8.97 Million |
| Active Biotech AB (ACTI) | $188.64 Million | -118.73% | 1.64x | $17.19 Million |
| Alzinova AB (ALZ) | $20.63 Million | -16.51% | 0.08x | $4.97 Million |
| AlzeCure Pharma (ALZCUR) | $182.01 Million | -28.02% | 0.03x | $18.18 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $14.33 Million |
| BioInvent International AB (BINV) | $219.00 Million | -63.86% | 0.22x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.59 Billion |
About Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more